US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities in digitally enabled studies.
The Partner Program runs on the company’s platform and aims to enable CROs to reduce clinical trial timelines by at least 50%, providing both administrative and financial benefits.
Go deeper with GlobalData
It is also designed to help CROs generate trial-specific quotes rapidly and enter trial kick-off or bid defence meetings with pre-built digital studies.
The Partner Program offers CROs a choice between self-service, managed service, or a hybrid support model, with the aim to deliver higher margin services through the use of generative AI.
Among the programme’s features are tools for pricing, demo support for bid defence meetings, and a content library to facilitate reuse and scalability.
One of its key components is access to Studio, Medable’s AI-powered tool for creating, storing and reusing eCOA instruments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataStudio is designed to allow CROs to build eCOA assessments and deploy trials independently, providing the flexibility they need to scale their operations.
Its features include content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder.
Medable chief customer officer Alison Holland said: “We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process.
“Medable’s Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable’s vision of a one-day study start.”
Based in California, Medable offers a digital clinical trials platform that has been used in nearly 400 trials across 70 countries to date.
The company recently launched a digital-first long-term follow-up model intended to reduce burdens on sites and participants in cell and gene therapy trials.
